Thursday, July 16, 2015
Grand Hall and Gallery, Ground Floor & 1st Floor (Maritim Hotel)
Thomas Clavel
,
Technische Universität München, ZIEL Research Center for Nutrition and Food Sciences, Freising-Weihenstephan, Germany
Thomas Lee
,
University of Alberta, Edmonton, AB, Canada
Annemarie Schmidt
,
Technische Universitaet Muenchen, Freising, Germany
Kirill Smirnov
,
German Research Center for Environmental Health, Neuherberg, Germany
Ilias Lagkouvardos
,
Technische Universität München, ZIEL Research Center for Nutrition and Food Sciences, Freising-Weihenstephan, Germany
Alesia Walker
,
German Research Center for Environmental Health, Neuherberg, Germany
Marianna Lucio
,
German Research Center for Environmental Health, Neuherberg, Germany
Philippe Schmitt-Kopplin
,
German Research Center for Environmental Health, Neuherberg, Germany
Richard Fedorak
,
University of Alberta, Edmonton, AB, Canada
Dirk Haller
,
Technische Universität München, Chair of Nutrition and Immunology, Freising-Weihenstephan, Germany
Iron deficiency is a common complication in patients with inflammatory bowel diseases (IBD) and oral iron therapy is suggested to change the gut microbial ecosystem and to exacerbate IBD symptoms.
We performed an open-labelled clinical trial to compare the effects of oral (PO) vs. intravenous (IV) iron replacement therapy (IRT) in patients with Crohn’s disease (CD; N = 31), ulcerative colitis (UC; N = 22) and iron deficient controls (NI = 19). After 3 months, changes in disease activity were independent of iron sulphate (PO) or iron sucrose (IV) treatments. However, high-throughput 16S rRNA gene sequencing of fecal samples identified marked inter-individual differences, lower phylotype richness and proportions of Clostridiales in IBD patients. Major shifts in bacterial diversity occurred in approximately half of all participants after IRT, but CD patients were most susceptible. High-resolution mass spectrometry showed clear separations of both UC and CD from anemic controls. IV- and PO-specific fingerprints were evident at the level of metabolomes, with changes affecting cholesterol-derived host substrates.
In conclusion, bacterial diversity and composition associated with iron therapy are altered in IBD participants. Oral iron administration affects bacterial phylotypes and fecal metabolites compared to IV therapy independent of the clinical outcome.
